Karoline Kielbassa, PhD student

Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Department of Experimental Immunology, Amsterdam UMC location AMC, Amsterdam, Netherlands.

Member of T2B WP 2&5.

Since January 2019, I am pursuing a PhD program under supervision of Eric Eldering, Arnon P. Kater and Taco Kuijpers at the Amsterdam UMC,, location AMC. I am studying the selective effects of BTK and novel inhibitors of Bcl-2 family members in both healthy and malignant post-B-cell activation pathways of plasma cell differentiation and survival.

Besides studying the effects in chronic lymphocytic leukemia (CLL), we are also interested whether those inhibitors of Bcl-2 family members can be applied in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis

Recent publications

  1. Changes in BcL-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to vnetoclax in CLL. Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, Tam C, Forconi F, Chiodin G, Brown JR, Dubois J, Kater AP, Eldering E. Blood. 2020 Jun 30